OxFORD Asset Management LLP reduced its stake in Anika Therapeutics Inc. (NASDAQ:ANIK) by 42.7% in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 34,365 shares of the biotechnology company’s stock after selling 25,651 shares during the quarter. OxFORD Asset Management LLP owned approximately 0.23% of Anika Therapeutics worth $1,696,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds also recently bought and sold shares of ANIK. Great West Life Assurance Co. Can lifted its holdings in Anika Therapeutics by 10.3% in the 1st quarter. Great West Life Assurance Co. Can now owns 21,220 shares of the biotechnology company’s stock worth $921,000 after purchasing an additional 1,974 shares during the last quarter. First Trust Advisors LP increased its position in Anika Therapeutics by 11.9% in the 1st quarter. First Trust Advisors LP now owns 13,245 shares of the biotechnology company’s stock worth $575,000 after buying an additional 1,410 shares during the period. Bank of New York Mellon Corp increased its position in Anika Therapeutics by 7.5% in the 1st quarter. Bank of New York Mellon Corp now owns 277,378 shares of the biotechnology company’s stock worth $12,049,000 after buying an additional 19,457 shares during the period. Comerica Bank increased its position in Anika Therapeutics by 4.3% in the 1st quarter. Comerica Bank now owns 16,519 shares of the biotechnology company’s stock worth $756,000 after buying an additional 685 shares during the period. Finally, Ameriprise Financial Inc. increased its position in Anika Therapeutics by 28.6% in the 1st quarter. Ameriprise Financial Inc. now owns 118,456 shares of the biotechnology company’s stock worth $5,146,000 after buying an additional 26,362 shares during the period. Hedge funds and other institutional investors own 84.32% of the company’s stock.
Shares of Anika Therapeutics Inc. (NASDAQ ANIK) opened at 59.58 on Wednesday. The stock’s 50 day moving average price is $56.73 and its 200-day moving average price is $49.81. Anika Therapeutics Inc. has a 52-week low of $41.38 and a 52-week high of $60.27. The company has a market capitalization of $873.32 million, a PE ratio of 26.47 and a beta of 1.66.
Anika Therapeutics (NASDAQ:ANIK) last released its earnings results on Wednesday, July 26th. The biotechnology company reported $0.76 EPS for the quarter, beating the Zacks’ consensus estimate of $0.44 by $0.32. The business had revenue of $33.50 million for the quarter, compared to analysts’ expectations of $27.20 million. Anika Therapeutics had a return on equity of 14.88% and a net margin of 30.44%. The firm’s revenue was up 25.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.57 earnings per share. On average, analysts expect that Anika Therapeutics Inc. will post $2.20 earnings per share for the current year.
ANIK has been the topic of several recent analyst reports. BidaskClub raised Anika Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, August 8th. Zacks Investment Research upgraded Anika Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 2nd.
ILLEGAL ACTIVITY NOTICE: This news story was originally published by BBNS and is the property of of BBNS. If you are reading this news story on another site, it was illegally copied and republished in violation of United States and international copyright legislation. The correct version of this news story can be viewed at https://baseballnewssource.com/markets/oxford-asset-management-llp-decreases-position-in-anika-therapeutics-inc-anik/1701216.html.
In other news, CEO Charles H. Sherwood sold 7,124 shares of the firm’s stock in a transaction dated Friday, October 13th. The stock was sold at an average price of $60.08, for a total transaction of $428,009.92. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Charles H. Sherwood sold 63,799 shares of the firm’s stock in a transaction dated Thursday, July 27th. The shares were sold at an average price of $50.79, for a total value of $3,240,351.21. Following the transaction, the chief executive officer now directly owns 174,705 shares in the company, valued at $8,873,266.95. The disclosure for this sale can be found here. 6.57% of the stock is owned by corporate insiders.
Anika Therapeutics Profile
Anika Therapeutics, Inc is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration.
Receive News & Ratings for Anika Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics Inc. and related companies with our FREE daily email newsletter.